Autologous Fibrin Glue Reinforced by Platelets in Surgery of Ascending Aorta[*]

Abstract

Objectives: Fibrin sealants are popular for the improvement of perioperative hemostasis and reducing blood transfusion needs. Biological glues prepared from pooled human donor plasma have an inherent risk of transmission of blood-borne disease and are quite expensive to use. A system for the production of autologous fibrin sealant reenforced by platelets has been developed. Its efficacy, safety and economic benefits have been evaluated in a prospective, randomized study. Material: 20 consecutive patients undergoing replacement of the ascending aorta by the same surgical team had local application of either Tissucol™ (Group A) or autologous fibrin glue (Group B) for hemostasis. Results: No adverse effects of either glue were recorded. The volume of produced autologous fibrin glue was 25 cc PRP. Platelet yield was 72 %. The two groups were comparable. Efficacy was group comparable. Average cost for sealants in Group A was 470 ± 100 Euros compared to 273 Euros in Group B, p = 0.004. Conclusions: Autologous fibrin glue reenforced by autologous platelets can be safely produced in the operating room in a large volume, with an comparable efficacy at a lower cost than commercial sealants.

Surgery of ascending aorta - surgical glue - hemostasis - hemorrhage - costs

References

• 1 Carless P A, Anthony D M, Henry D A. Systemic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion.  Br J Surg. 2002;  89 695-703
• 2 Borst H G, Haverich A, Walterbusch G. et al . Fibrin adhesive: an important hemostatic adjunct in cardiovascular operations.  J Thorac Cardiovasc Surg. 1982;  84 548-553
• 3 Mathew T L, Spotnitz W D, Kron I L. et al . Four years' experience with fibrin sealant in thoracic and cardiovascular surgery.  Ann Thorac Surg. 1990;  50 40-44
• 4 Seguin J R, Picard E, Frapier J M, Chaptal P A. Aortic valve repair with fibrin glue for type A acute aortic dissection.  Ann Thorac Surg. 1994;  58 304-307
• 5 Radosevich M, Goubran H A, Burnouf T. Fibrin sealant: scientific rationale, production methods, properties and current clinical use.  Vox Sang. 1997;  72 133-143
• 6 Jackson M R. Fibrin sealants in surgical practice: An overview.  Am J Surg. 2001;  182 (Suppl) 1S-7S
• 7 Spotnitz W D. Commercial fibrin sealants in surgical care.  Am J Surg. 2001;  182 (Suppl) S8-14
• 8 Kawamura M, Sawafuji M, Watanabe M. et al . Frequency of transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery.  Ann Thorac Surg. 2002;  73 1098-1100
• 9 Kjaergard H K, Trumbull H R. Vivostat system autologous fibrin sealant: preliminary study in elective coronary bypass grafting.  Ann Thorac Surg. 1998;  66 482-486
• 10 Man D, Plosker H, Winland-Brown J E. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery.  Plastic Reconstr Surg. 2001;  107 229-239
• 11 Fang W C, Helm R E, Krieger K H. et al . Impact of minimum hematocrit during cardiopulmonary bypass on mortality in patients undergoing coronary artery surgery.  Circulation. 1997;  96 (Suppl II) II-194-199
• 12 Kjaergard H K, Fairbrother J E. Controlled clinical studies of fibrin sealant in cardiovascular surgery: a review.  Eur J Cardiothorac Surg. 1996;  10 727-733
• 13 Mankad P S, Codispoti M. The role of fibrin sealants in hemostasis.  Am J Surg. 2001;  182 21S-28S
• 14 Sellman M, Intonti M A, Ivert L. Reoperations for bleeding after coronary artery bypass procedures during 25 years.  Eur J Cardiothoracic Surg. 1997;  11 521-527
• 15 Christenson J T, Reuse J, Badel P. et al . Autologous platelet sequestration in patients undergoing coronary artery bypass grafting. A prospective randomized study.  Eur J Cardiothorac Surg. 1996;  10 1083-1089
• 16 Spotnitz W D. Fibrin sealant in the United States: clinical use at the University of Virginia.  Thromb Haemost. 1995;  47 482-485
• 17 Milne A A, Murphy W G, Reading S J, Ruckley C V. Fibrin sealant reduces suture line bleeding during carotid endarterectomy: a randomized trial.  Eur J Endovasc Surg. 1995;  10 91-94
• 18 Schuele A M, Beierlein M S, Wendel H P. et al . Fibrin sealant, aprotinin, and immune response in children undergoing operations for congenital heart disease.  J Thorac Cardiovasc Surg. 1998;  115 883-889
• 19 Tawes Jr R L, Sydorak G R, DuVall T B. Autologous fibrin glue: the last step in operative hemostasis.  Am J Surg. 1994;  168 120-122
• 20 Pierce G F, Mustoe T A, Altrock B W, Deuel T F, Thomason A. Role of platelet derived growth factor in wound healing.  J Cell Biochem. 1991;  45 319-326

1 Presented at 4th joint meeting of the German, Austrian and Swiss Societies for Thoracic and Cardiovascular Surgery, February 15 - 18, 2004, Hamburg, Germany